Beckman Coulter discovered a significant difference between the two standard prostate cancer screening (PSA) scores, a discrepancy that could have major impact on physicians’ cancer diagnoses. The challenge was how to communicate this in a simple and powerful way.
Focusing on the difference gap of 22%, this integrated campaign was hugely successful at helping Beckman Coulter rethink vendor relationships, assure accuracy and influence care decisions.
